What factors should be considered when deciding whether to refer a patient for CAR T-cell therapy?

During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What factors should be considered when deciding whether to refer a patient for chimeric antigen receptor (CAR) T-cell therapy?

In this podcast, Jäger discusses the factors that should be considered when selecting patients for CAR T-cell therapy. He analyzes elements of the disease and biomarkers that can help predict response to CAR T-cell treatment. Finally, Jäger describes the two different approaches in regards to the use of CAR T-cell therapy that exist in this field.

Hosted on Acast. See acast.com/privacy for more information.